Detemir Energy Expenditure Study (DEES)
A 24-week, National, Single-centre, Open-labelled, Randomised, Parallel-group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes
Sponsor: Novo Nordisk A/S
Listed as NCT00788840, this PHASE4 trial focuses on Obesity and Type 2 Diabetes Mellitus and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
-
Jan 2021 — Jun 2023 [monthly]
Unknown Status PHASE4
-
Feb 2017 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE4
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
- University of Surrey
For direct contact, visit the study record on ClinicalTrials.gov .